论文部分内容阅读
目的:探讨亚胺培南与西司他丁联合去甲万古霉素对重症获得性下呼吸道感染患者治疗效果。方法:回顾性分析获得性下呼吸道感染患者70例临床资料,其中36例为观察组,采用亚胺培南与西司他丁联合去甲万古霉素治疗;其余34例为对照组,采用哌拉西林与他唑巴坦联合左氧氟沙星沙星治疗。比较两组患者治疗7天后的效果、症状缓解时间、治愈时间、住院花费及不良反应发生率。结果:观察组有效率高于对照组,差异有统计学意义(P<0.05);观察组症状缓解时间及治愈时间较对照组短,但住院花费高于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率高于对照组,差异有统计学意义(P<0.05)。结论:亚胺培南与西司他丁联合去甲万古霉素对获得性下呼吸道感染患者治疗显著,但不良反应较多,需临床加以重视。
Objective: To investigate the therapeutic effect of imipenem and cilastatin combined with norvancomycin on patients with severe acquired lower respiratory tract infection. Methods: A retrospective analysis of 70 patients with acquired lower respiratory tract infection in clinical data, of which 36 cases were observed with imipenem and cilastatin plus norvancomycin treatment; the remaining 34 cases of control group, using piperazine Laceillin and tazobactam in combination with levofloxacin and sand star therapy. The effect, symptom relief time, cure time, hospitalization expense and incidence of adverse reactions were compared between the two groups after 7 days of treatment. Results: The effective rate of the observation group was higher than that of the control group (P <0.05); the symptom relief time and the cure time of the observation group were shorter than those of the control group, but the hospitalization cost was higher than that of the control group (P <0.05). The incidence of adverse reactions in the observation group was higher than that in the control group (P <0.05). Conclusion: The combination of imipenem and cilastatin combined with norvancomycin has a significant effect on patients with acquired lower respiratory tract infection, but there are more adverse reactions, which require clinical attention.